ArticleBMC pulmonary medicine2025
Characteristics and risk factors for thrombocytopenia in malignancy patients with pulmonary embolism: a case control study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThrombocytopenia represents a frequent yet severe complication among malignancy patients with pulmonary embolism (PE). Contrary to the assumption that low platelet counts might inhibit thrombosis, thrombocytopenia in malignancy patients poses significant challenges for anticoagulation therapy. This study aimed to investigate the clinical characteristics and identify risk factors associated with thrombocytopenia in malignancy patients complicated by PE. The findings may provide a foundation for developing targeted interventions to mitigate thrombocytopenia and guide biomarker and clinical characteristics-based management strategies.
methodsWe conducted a retrospective study analyzing clinical data from malignancy patients diagnosed with PE who were admitted to the Second Affiliated Hospital of Kunming Medical University between January 2014 and June 2024. The cohort was stratified into two groups: 66 patients with thrombocytopenia and 429 patients with normal platelet counts. Clinical characteristics and potential risk factors were systematically collected and analyzed.
resultsMany clinical indicators were found to have statistically significant differences between the low platelet group and the normal platelet group (P < 0.05). Multivariable logistic regression analysis further identified coronary heart disease, right ventricular dysfunction, anticoagulant therapy, anti-tumor drug therapy, dyspnea, hemoptysis, fever(>37.3℃), neutrophil (NEUT), standard deviation in red cell distribution width (RDWSD), platelet distribution width (PDW), procalcitonin (PCT), international normalized ratio (INR), fibrinogen (FIB) were significantly associated with a 6.703, 3.335, 0.311, 4.176, 4.244, 4.533, 3.527, 0.288, 3.995, 2.616, 5.129, 2.641, 0.212 times higher risk of thrombocytopenia in malignant patients with PE respectively.
conclusionMultivariate analysis identified several independent risk factors for thrombocytopenia in malignant patients with PE, including coronary heart disease, right ventricular dysfunction, anti-tumor drug therapy, dyspnea, hemoptysis, fever (> 37.3 °C), RDW-SD, PDW, PCT and INR. Conversely, anticoagulant therapy, NEUT, and FIB emerged as independent protective factors against thrombocytopenia in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.